PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

被引：0

作者：

Wu, Jing ^{[1
]}

Bryla, Christine ^{[1
]}

Su, Yu-Ting ^{[1
]}

Grajkowska, Ewa ^{[1
]}

McCoy, Ann ^{[2
]}

Boris, Lisa ^{[1
]}

Antony, Ramya ^{[1
]}

Garren, Nancy ^{[2
]}

Siegel, Christine ^{[1
]}

Cordova, Christine ^{[1
]}

Aboud, Orwa ^{[1
]}

Vera, Elizabeth ^{[1
]}

Lawhon, Tracy ^{[3
]}

Penas-Prado, Marta ^{[1
]}

Theeler, Brett ^{[1
]}

Mendoza, Tito ^{[4
]}

Armstrong, Terri ^{[1
]}

Yuan, Ying ^{[4
]}

Gilbert, Mark ^{[1
]}

机构：

[1] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] NCI, Bethesda, MD 20892 USA

[3] Adastra Pharmaceut Inc, San Diego, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-62

引用

页码：27 / 28

页数：2

共 50 条

[41] A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma
Gilbert, Mark R.
Yuan, Ying
Wu, Jimin
Mendoza, Tito
Vera, Elizabeth
Omuro, Antonio
Lieberman, Frank
Robins, H. Ian
Gerstner, Elizabeth R.
Wu, Jing
Wen, Patrick Y.
Mikkelsen, Tom
Aldape, Kenneth
Armstrong, Terri S.
NEURO-ONCOLOGY, 2021, 23 (03) : 468 - 477
[42] A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Kreisl, Teri N.
Kotliarova, Svetlana
Butman, John A.
Albert, Paul S.
Kim, Lyndon
Musib, Luna
Thornton, Donald
Fine, Howard A.
NEURO-ONCOLOGY, 2010, 12 (02) : 181 - 189
[43] A PHASE I ASCENDING DOSE TRIAL OF THE SAFETY AND TOLERABILITY OF TOCA 511 IN SUBJECTS WITH RECURRENT HIGH-GRADE GLIOMA
Pertschuk, Daniel
Cloughesy, Timothy F.
Chang, Susan M.
Aghi, Manish K.
Vogelbaum, Michael A.
Liau, Linda M.
Shafa, Bob
Jolly, Douglas J.
Ibanez, Carlos E.
Perez, Omar D.
Robbins, Joan M.
Gruber, Harry E.
NEURO-ONCOLOGY, 2011, 13 : 90 - 90
[44] Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Zhou, Zhengqiu
Howard, Tracy A.
Villano, John L.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) : 1043 - 1046
[45] Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Zhengqiu Zhou
Tracy A. Howard
John L. Villano
Cancer Chemotherapy and Pharmacology, 2017, 80 : 1043 - 1046
[46] RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM)
Gilbert, Mark R.
Wang, Meihua
Aldape, Kern
Sorensen, A. Gregory
Mikkelsen, Tom
Bokstein, Felix
Woo, Shaio Y.
Chmura, Steven J.
Choucair, Ali K.
Mehta, Minesh
NEURO-ONCOLOGY, 2010, 12 : 39 - 39
[47] Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas
Huang, Mengqian
Kang, Zhuang
Li, Shenglan
Zhang, Botao
Xiao, Yantao
Li, Shangwei
Li, Wenbin
NEOPLASIA, 2025, 61
[48] A PHASE 0/1 'TRIGGER' TRIAL OF RIBOCICLIB PLUS EVEROLIMUS IN RECURRENT HIGH-GRADE GLIOMA
Sanai, Nader
Tien, An-Chi
Jiang, Jun
Chang, Yu-Wei
Pennington-Krygier, Chelsea
DeSantis, Anita
Fujita, Yoko
Kim, Seongho
Li, Jing
Mehta, Shwetal
NEURO-ONCOLOGY, 2021, 23 : 64 - 64
[49] A PHASE 0/1 'TRIGGER' TRIAL OF RIBOCICLIB PLUS EVEROLIMUS IN RECURRENT HIGH-GRADE GLIOMA
Sanai, Nader
Tien, An-Chi
Jiang, Jun
Chang, Yu-Wei
Montgomery, Chelsea
DeSantis, Anita
Fujita, Yoko
Kim, Seongho
Mehta, Shwetal
NEURO-ONCOLOGY, 2022, 24 : 84 - 84
[50] A PHASE 0/1 'TRIGGER' TRIAL OF RIBOCICLIB PLUS EVEROLIMUS IN RECURRENT HIGH-GRADE GLIOMA
Sanai, N.
Tien, A.
Jiang, J.
Chang, Y.
Pennington-Krygier, C.
DeSantis, A.
Fujita, Y.
Kim, S.
Li, J.
Mehta, S.
NEURO-ONCOLOGY, 2021, 23 : 8 - 8

← 1 2 3 4 5 →